Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Lipids are the fatty molecules that make up cellular membranes, creating a protective barrier that regulates what enters and ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Johnson & Johnson’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Same-arm booster shots trigger a stronger early immune response than shots given in the opposite arm, leading to higher ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Adults with eosinophilic esophagitis may have elevated levels of multiple food allergen–specific antibody types other than ...

Discover how early functional screening at the single-cell level transforms therapeutic development of your antibodies.

Scientists have uncovered why vaccines can elicit a stronger immune response if they are administered in the same arm.